Our latest articles
Look out Amryt: Krystal’s topical gene therapy is gaining ground.
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.